ATNM News and Press, Actinium Pharmaceuticals Inc. From 12/29/20

Shares of Actinium Pharmaceuticals (ATNM) surge 22% in morning trade after an Independent Data Monitoring Committee recommended ((DMC)) that its late-stage SIERRA trial should continue as planned to full enrollment of 150 patients.The trial tests the safety and effectiveness of Iomab-B f...

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial - 100% rate of BMT and engraftment in patients receiving therapeutic dose of Iomab-B and lower rates of sepsis and sepsis related Grade ≥3 adverse events compared to patients receivi...

Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit NEW YORK , Dec. 9, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Targeted Radiopharmace...

Actinium Pharmaceuticals ([[ATNM]] +1.2%)  announced its first-in-human data from the first dose cohort of the Phase 1 portion of the Actimab-A + venetoclax combination Phase 1/2 trial for patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML).Data...

Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH NEW YORK , Dec. 8, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"...

Actinium Pharmaceuticals ([[ATNM]] -0.2%) has reported interim data from its ongoing Phase 3 SIERRA trial evaluating the company's lead candidate, I-131 apamistamab (Iomab-B) in patients with relapsed or refractory Acute Myeloid Leukemia. Data were presented at t...

Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting NEW YORK , Dec. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: A...

Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting NEW YORK , Dec. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that safety data fro...

Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting NEW YORK , Dec. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today a...

Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting NEW YORK , Dec. 3, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted that four abstracts detail...